In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


TKT: Victory At Last

Executive Summary

The recent UK appeals court decision that TKT does not infringe Amgen's erythropoeitin patent doesn't mean much commercially for either group. But it could pave the way for stricter interpretation of biotech patents in the UK and the rest of Europe.

You may also be interested in...

Why EPO Matters

Dramatic events in the EPO market--roiled by patent fights, biosimilars, and next-generation products--are important not merely to the current EPO players. They affect nearly all large-molecule companies.

TKT: Bloodied But Unbowed

Amgen was the winner of a late January decision involving its patent dispute with Transkaryotic Therapies Inc. over erythropoietin. Its stock rose about 15% in the three days after the ruling, while TKT's shares slid 40% that week. The judge ruled that TKT's process doesn't infringe Amgen's patent, but the product that TKT makes using that process does. The decision is on appeal. TKT argues that its method is a next-generation protein production technology, but if the decision stands, the company will have to take its first shot at something other than EPO.

Why Amgen vs. TKT Matters

Amgen's patent infringement lawsuit against Transkaryotic Therapies is probably the most important of its kind, and not merely because the product Amgen is trying to protect, erythropoietin, is the company's--and the biotech industry's--biggest revenue generator. This lawsuit, although not yet decided, already offers some valuable lessons both in developing a patent portfolio and defending a patented product.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts